From: Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung Cancer
AdCCL21-DC
Recovery
Viability
CCL21
37°C
RT
ng/1 × 106
Ng/1 × 106
%
24 h
48
50.7 ± 14
59 ± 0.03
75 ± 0.2
*93.6 ± 0.02
1.1 ± 0.7
1.9 ± 1.3
2.9 ± 2.1
3.7 ± 2.5